Close Menu

NEW YORK – Daiichi Sankyo and Goustave Roussy have entered into a multi-year collaboration to study and develop two of Daiichi's lead DXd antibody drug conjugates, DS-1062 and patritumab deruxtecan, in lung and breast cancer indications and look for biomarkers of response and resistance.

Under the terms of the agreement, Daiichi will provide funding and support to Gustave Roussy for clinical, translational, and preclinical studies involving these two agents.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.